Development of a Direct-to-Biology Platform to Discover Potent MNK Inhibitors.

Area of Science:

• Molecular Biology
• Cancer Research
• Drug Discovery

Background:

• Eukaryotic translation initiation factor 4E (eIF4E) drives cell proliferation by promoting mRNA translation.
• eIF4E activity is regulated by MNK1/2 kinases via phosphorylation at Ser209.
• Elevated eIF4E phosphorylation contributes to malignant progression in cancers like glioblastoma.

Purpose of the Study:

• To develop and apply a direct-to-biology (D2B) platform for rapid optimization of MNK inhibitors.
• To identify novel compounds with potent cellular inhibition of MNK kinases.

Main Methods:

• Combined plate-based library synthesis with in-cell Western assays.
• Utilized the D2B platform to generate structure-activity relationship (SAR) data.
• Synthesized and tested over 150 novel analogs directly in cancer cells.

Main Results:

• Identified potent MNK inhibitors with IC50 values as low as 23 nM in LN229 glioblastoma cells.
• Demonstrated the efficiency of the D2B platform in structure-activity relationship (SAR) studies.
• Successfully optimized new compounds for cellular inhibition.

Conclusions:

• The direct-to-biology (D2B) platform is an effective strategy for efficient kinase inhibitor optimization.
• This approach accelerates the discovery of potent inhibitors targeting key cancer pathways.
• The developed inhibitors show promise for targeting eIF4E-driven cancers.